Qualigen Therapeutics Partners With TD2 For Phase 1 Clinical Development Of QN-302 For The Treatment Of Advanced Or Metastatic Solid Tumors
Qualigen Therapeutics Partners With TD2 For Phase 1 Clinical Development Of QN-302 For The Treatment Of Advanced Or Metastatic Solid Tumors
Qualigen Therapeutics 与 TD2 合作开发用于治疗晚期或转移性实体瘤的 QN-302 的 1 期临床开发
Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today it is partnering with Translational Drug Development (TD2) as the contract research organization (CRO) to conduct the Phase 1 clinical development of lead drug candidate QN-302. Qualigen received US FDA IND clearance earlier this month to initiate a Phase 1 clinical trial of QN-302, a small molecule G-Quadruplex (G4)-selective transcription inhibitor, for the treatment of advanced or metastatic solid tumors.Â
专注于开发可能被指定为孤儿药的成人和儿科癌症的临床阶段治疗公司Qualigen Therapeutics, Inc.（纳斯达克股票代码：QLGN）今天宣布，它将与转化药物开发（TD2）合作，作为合同研究组织（CRO）进行主要候选药物 QN-302 的第一阶段临床开发。本月早些时候，Qualigen获得了美国食品药品管理局的IND许可，可以启动一项针对治疗晚期或转移性实体瘤的小分子G-Qualplex（G4）选择性转录抑制剂 QN-302 的1期临床试验。A
Tariq Arshad, M.D., M.B.A., Chief Medical Officer, stated: "I am delighted...
医学博士、工商管理硕士、首席...
登录免费看全文
登录/注册